Interim Report January - June 2024: Strong Sales Growth in US Market
Senzime AB (STO:SEZI)(OTCQX:SNZZF) has released its interim report for January - June 2024, showing strong sales growth, particularly in the US market. Key highlights include:
- Net sales increased by 76% to TSEK 14,917 in Q2 2024
- US net sales grew by 167% to TSEK 10,973 in Q2 2024
- Disposable sensor sales rose by 92% to TSEK 8,412 in Q2 2024
- Gross margin before depreciation was 63.3% in Q2 2024
- Cash and cash equivalents stood at TSEK 80,184 as of June 30th
CEO Philip Siberg noted the company's success in gaining market share and establishing its technology as the new clinical standard in operating rooms worldwide. The expanded US sales organization has proven effective, with increased system utilization and nearly doubled disposable sensor deliveries compared to the previous year.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) ha pubblicato il suo rapporto intermedio per il periodo gennaio - giugno 2024, evidenziando una forte crescita delle vendite, soprattutto nel mercato statunitense. I principali punti salienti includono:
- Le vendite nette sono aumentate del 76% a TSEK 14,917 nel Q2 2024
- Le vendite nette negli Stati Uniti sono cresciute del 167% a TSEK 10,973 nel Q2 2024
- Le vendite di sensori monouso sono aumentate del 92% a TSEK 8,412 nel Q2 2024
- Il margine lordo prima dell'ammortamento era del 63,3% nel Q2 2024
- La liquidità e le equivalenti ammontavano a TSEK 80,184 al 30 giugno
Il CEO Philip Siberg ha osservato il successo dell'azienda nell'acquisire quote di mercato e nell'affermare la propria tecnologia come nuovo standard clinico nelle sale operatorie di tutto il mondo. L'organizzazione di vendita ampliata negli Stati Uniti si è rivelata efficace, con un aumento dell'utilizzo dei sistemi e quasi raddoppiate le consegne di sensori monouso rispetto all'anno precedente.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) ha publicado su informe interino para enero - junio de 2024, mostrando un fuerte crecimiento en las ventas, particularmente en el mercado de EE.UU. Los puntos clave incluyen:
- Las ventas netas aumentaron un 76% a TSEK 14,917 en el Q2 2024
- Las ventas netas en EE.UU. crecieron un 167% a TSEK 10,973 en el Q2 2024
- Las ventas de sensores desechables aumentaron un 92% a TSEK 8,412 en el Q2 2024
- El margen bruto antes de depreciación fue del 63.3% en el Q2 2024
- El efectivo y equivalentes equivalían a TSEK 80,184 al 30 de junio
El CEO Philip Siberg comentó sobre el éxito de la compañía en ganar cuota de mercado y establecer su tecnología como el nuevo estándar clínico en las salas de operaciones de todo el mundo. La organización de ventas ampliada en EE.UU. ha demostrado ser efectiva, con un aumento en la utilización de los sistemas y casi el doble de entregas de sensores desechables en comparación con el año anterior.
Senzime AB (STO:SEZI)(OTCQX:SNZZF)는 2024년 1월 - 6월 Interim Report를 발표하였으며, 미국 시장에서 견고한 매출 성장을 보여주고 있습니다. 주요 하이라이트는 다음과 같습니다:
- 2024년 2분기 순매출이 76% 증가하여 TSEK 14,917에 도달
- 미국 순매출이 167% 증가하여 TSEK 10,973에 도달
- 일회용 센서 매출이 92% 증가하여 TSEK 8,412에 도달
- 감가상각 전 총 마진은 2024년 2분기 기준 63.3%
- 6월 30일 기준 현금 및 현금성 자산은 TSEK 80,184에 달함
CEO인 Philip Siberg는 회사가 시장 점유율을 확보하고 해당 기술을 전 세계 수술실의 새로운 임상 표준으로 확립하는 데 성공했다고 언급했습니다. 확대된 미국 영업 조직의 효과가 입증되었으며, 시스템 활용도가 증가하고 지난해와 비교해 일회용 센서 배송량이 거의 두 배로 증가했습니다.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) a publié son rapport intermédiaire pour la période de janvier à juin 2024, affichant une forte croissance des ventes, notamment sur le marché américain. Les principaux points forts incluent :
- Les ventes nettes ont augmenté de 76 % pour atteindre TSEK 14,917 au 2ème trimestre 2024
- Les ventes nettes aux États-Unis ont augmenté de 167 % pour atteindre TSEK 10,973 au 2ème trimestre 2024
- Les ventes de capteurs jetables ont augmenté de 92 % pour atteindre TSEK 8,412 au 2ème trimestre 2024
- La marge brute avant amortissement était de 63,3 % au 2ème trimestre 2024
- La trésorerie et équivalents de trésorerie s'élevaient à TSEK 80,184 au 30 juin
Le PDG Philip Siberg a noté le succès de l'entreprise dans l'acquisition de parts de marché et l'établissement de sa technologie comme le nouveau standard clinique dans les salles d'opération du monde entier. L'organisation des ventes élargie aux États-Unis s'est révélée efficace, avec une augmentation de l'utilisation des systèmes et une quasi-doublage des livraisons de capteurs jetables par rapport à l'année précédente.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) hat ihren Zwischenbericht für Januar - Juni 2024 veröffentlicht und zeigt ein starkes Umsatzwachstum, insbesondere im US-Markt. Zu den wichtigsten Ergebnissen gehören:
- Nettoverkaufszahlen stiegen im 2. Quartal 2024 um 76% auf TSEK 14,917
- Die Nettoverkäufe in den USA wuchsen im 2. Quartal 2024 um 167% auf TSEK 10,973
- Die Verkäufe von Einweg-Sensoren stiegen um 92% auf TSEK 8,412 im 2. Quartal 2024
- Die Bruttomarge vor Abschreibungen betrug 63,3% im 2. Quartal 2024
- Der Bargeldbestand und Bargeldäquivalente betrugen zum 30. Juni TSEK 80,184
CEO Philip Siberg bemerkte den Erfolg des Unternehmens bei der Gewinnung von Marktanteilen und der Etablierung seiner Technologie als neuen klinischen Standard in Operationssälen weltweit. Die erweiterte Verkaufsorganisation in den USA hat sich als effektiv erwiesen, mit einer gestiegenen Systemnutzung und fast verdoppelten Lieferungen von Einweg-Sensoren im Vergleich zum Vorjahr.
- None.
- None.
UPPSALA, SWEDDEN / ACCESSWIRE / August 26, 2024 / Senzime (STO:SEZI)(OTCQX:SNZZF) Press release: Uppsala, 26 August 2024. Senzime AB:s (publ) interim report for January - June 2024 is now available on the company's website www.senzime.com.
Financial information April - June 2024
Net sales amounted to TSEK 14,917 (8,462), an increase of 76 percent.
Sales of disposable sensors amounted to TSEK 8,412 (4,390), an increase of 92 percent.
In the USA, net sales increased to TSEK 10,973 (4,108), an increase of 167 percent.
The gross margin before depreciation amounted to 63.3 percent (70.0).
Operating costs amounted to TSEK 39,770 (37,101).
Operating profit before depreciation amounted to TSEK -29,239 (-30,201).
The result after financial items amounted to TSEK -34,259 (-35,264).
Earnings per share amounted to SEK -0.28 (-0.42).
Cash and cash equivalents as of June 30th amounted to TSEK 80,184 (41,635).
Financial information January - June 2024
Net sales amounted to TSEK 27,037 (15,750), an increase of 72 percent.
Sales of disposable sensors amounted to TSEK 15,668 (8,234), an increase of 90 percent.
In the USA, net sales increased to TSEK 20,011 (9,182), an increase of 118 percent.
The gross margin before depreciation amounted to 63.7 percent (69.3).
Operating costs amounted to TSEK 72,576 (69,479).
Operating profit before depreciation amounted to TSEK -53,150 (-56,661).
The result after financial items amounted to TSEK -62,978 (-66,955).
Earnings per share amounted to SEK -0.51 (-0.84).
Extract from the CEO comment:
Strong growth in the US market, we are gaining market share, and our technology is increasingly being established as the new clinical standard in operating rooms around the world
It has been another eventful quarter for Senzime. We continue to report strong growth and net sales increased by 76 percent vs Q2 2023 to SEK 14.9 million. Last year's second quarter included a one-off licensing revenue and excluding that, the sales increase was over 100 percent. This was again another quarter with record sales.
Our US revenue continues to develop strongly with an increase of 167 percent vs Q2 2023 Strategically important new hospital contracts and recurring sales of disposable sensors to the installed base of TetraGraph systems contributed to the growth. The expanded sales organization in the US is proving to be very successful. The utilization rate of systems continues to increase, and we delivered almost twice as many disposable sensors as the previous year.
Businesses in Japan and South Korea are also showing good growth. Our Japanese license partner Fukuda Denshi reports success in sales of its integrated module with "TetraGraph inside" launched in the first quarter of this year. The module is the first of its kind powered by our algorithms and sensors and launched as an accessory to Fukuda's extensive installed base of patient monitors. The healthcare strike in South Korea has continued, but despite this we have been able to once again deliver products to the market.
The focus and direction of Senzime is crystal clear - we are building the undisputed market leader in the digital and clinical shift that is now taking place in operating rooms worldwide. The commercial breakthrough for Senzime is a fact.
This press release only contains parts of the full interim report release that is published on Senzime's website: www.senzime.com.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com
About Senzime
Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com.
This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-26 08:00 CEST.
Attachments
SOURCE: Senzime
View the original press release on accesswire.com
FAQ
What was Senzime's (SNZZF) net sales growth in Q2 2024?
How much did Senzime's (SNZZF) US sales increase in Q2 2024?
What was the growth in Senzime's (SNZZF) disposable sensor sales for Q2 2024?
What was Senzime's (SNZZF) gross margin before depreciation in Q2 2024?
How much cash did Senzime (SNZZF) have on hand as of June 30, 2024?
